Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
BackgroundThe increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative...
Saved in:
| Main Authors: | Chiao-Ling Chen, Jian-Ying Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1407692/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
by: Dávid Száraz, et al.
Published: (2024-12-01) -
Glucocorticoids: A review of its adverse effects including bone loss
by: Amit Dua, et al.
Published: (2019-01-01) -
Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study
by: Tzai-Chiu Yu, et al.
Published: (2024-12-01) -
Current treatment of osteoporosis
by: Subramanian Nallasivan
Published: (2019-01-01) -
Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis
by: N.V. Grygorieva, et al.
Published: (2024-09-01)